Summary
Revlimid, a cancer drug derived from thalidomide, has generated over $100 billion in sales and extended thousands of lives, but its nearly $1,000-per-pill price has pushed many patients into debt.
Celgene, the original maker, exploited regulatory loopholes to block generics and inflate prices 26 times since 2005.
Despite costing just 25 cents to produce, Revlimid’s high price fueled lavish executive pay and Wall Street gains.
Even after generic entry, prices remain exorbitant. Critics, including patients and lawmakers, decry the drug’s pricing as exploitative and harmful.
a 400,000% markup on medically-necessary-to-live cancer pills
Every day I pray Brian Thompson’s killer wasn’t the only one (it wasn’t Luigi; he was at my house playing Stardew Valley).
I’m taking it that this is only the case in the US, again? I rather doubt it would be able to pull this shit in Europe or Canada.
Having said that, this is not that different from the Sacklers with the opioids. All pharmaceutical company executives that do this are cancers om humanity and deserve a meeting with the Luigi’s of this world
